IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock?
Ironwood's 110% monthly surge follows upbeat third-quarter results and raised 2025 outlook, powered by increasing Linzess demand.
IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars
Ironwood posts a stellar third-quarter beat with higher revenues and raises 2025 outlook on Linzess-driven strength.
Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On Monday - Cogent Biosciences ( NASDAQ:COGT ) , e.l.f. Beauty ( NYSE:ELF )
U.S. stocks were higher, with the Nasdaq Composite gaining more than 400 points on Monday. Shares of Pagaya Technologies Ltd ( NASDAQ:PGY ) rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results and raised its FY25 sales guidance.
Ironwood Pharmaceuticals ( IRWD ) Q3 Earnings and Revenues Surpass Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of +166.67% and +78.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Xencor ( XNCR ) Reports Q3 Loss, Misses Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of +88.89% and -18.15%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma Holdings, Inc. ( XERS ) Hit a 52 Week High, Can the Run Continue?
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
BioCryst ( BCRX ) Soars 6.1%: Is Further Upside Left in the Stock?
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Teladoc Health Expands Clarity Platform With Workplace Safety Tool
TDOC enhances its Clarity platform with an AI-driven tool to help hospitals combat rising workplace violence incidents.
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
Why Ironwood Pharmaceuticals ( IRWD ) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company - Cyclerion Therapeutics ( NASDAQ:CYCN )
CAMBRIDGE, Mass., Sept. 23, 2025 ( GLOBE NEWSWIRE ) -- Cyclerion Therapeutics, Inc. today announced that it has entered into a licensing agreement with the Massachusetts Institute of Technology ( "MIT" ) , securing the intellectual property that will serve as the cornerstone of its strategic ...
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
Cyclerion has entered into a licensing agreement with MIT, securing the intellectual property that will serve as the cornerstone of its strategic relaunch.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why American Eagle Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket - C3.ai ( NYSE:AI ) , American Eagle Outfitters ( NYSE:AEO )
Shares of American Eagle Outfitters, Inc. AEO rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results. American Eagle reported second-quarter revenue of $1.28 billion, beating analyst estimates of $1.24 billion, according to Benzinga Pro.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates
Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.
Ironwood ( IRWD ) Q2 EPS Jumps 600%
Ironwood Pharmaceuticals ( NASDAQ:IRWD ) , a specialty pharmaceutical company known for developing therapies for gastrointestinal conditions, delivered financial results on August 7, 2025, for its second quarter. The company beat analyst expectations on both non-GAAP earnings and GAAP revenue.
Ironwood Pharmaceuticals ( IRWD ) Beats Q2 Earnings and Revenue Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of +800.00% and +37.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients. multi-dosing is complete in first cohort ( 200 mg ) and single dosing is complete in second ...
Why Is Ironwood ( IRWD ) Down 18.4% Since Last Earnings Report?
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall.
Ironwood Pharmaceuticals ( IRWD ) Reports Q1 Loss, Misses Revenue Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of -180% and 21.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Vivos Therapeutics, Inc. ( VVOS ) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Vivos Therapeutics (VVOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion Pharmaceuticals ( RXRX ) Reports Q1 Loss, Misses Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -13.64% and 26.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ironwood Pharmaceuticals ( IRWD ) to Report a Decline in Earnings: What to Look Out for
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News
BMY and VERV are in the spotlight this week following the failure of a late-stage study and positive cholesterol study data, respectively.
Ironwood Shares Tank on Regulatory Update for Apraglutide
Per the latest discussion with the FDA, a confirmatory phase III study is required to seek approval for IRWD's apraglutide in short bowel syndrome with intestinal failure.
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - General Motors ( NYSE:GM ) , HCA Healthcare ( NYSE:HCA )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug - Ironwood Pharmaceuticals ( NASDAQ:IRWD )
27 apraglutide-treated patients achieved enteral autonomy in the long-term extension trial. NDA submission for apraglutide expected to be completed by Q3 2025. China's new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt Maley.
Crude Oil Moves Lower; M&T Bank Earnings Miss Views - Ironwood Pharmaceuticals ( NASDAQ:IRWD ) , MarineMax ( NYSE:HZO )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday. The Dow traded up 0.43% to 40,384.20 while the NASDAQ gained 0.33% to 16,778.86. The S&P 500 also rose, gaining, 0.55% to 5,392.71. Information technology shares surged by 2% on ...
Nasdaq Surges 2%; Goldman Sachs Posts Upbeat Earnings - Ironwood Pharmaceuticals ( NASDAQ:IRWD ) , Goldman Sachs Group ( NYSE:GS )
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 2% on Monday. The Dow traded up 0.99% to 40,610.00 while the NASDAQ gained 2.02% to 17,062.41. The S&P 500 also rose, gaining, 1.48% to 5,442.94. Information technology shares surged by 2.2% on Monday.
Corcept ( CORT ) Stock Jumps 109.1%: Will It Continue to Soar?
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Catalyst ( CPRX ) Surges 6.2%: Is This an Indication of Further Gains?
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down
Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025.
Ironwood Pharmaceuticals ( IRWD ) Q4 Earnings and Revenues Miss Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of -80% and 1.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls
Ironwood begins the rolling NDA filing for apraglutide to treat short bowel syndrome patients dependent on parenteral support.
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that go into effect in 2027.
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up
BEAM appoints Sravan K. Emany as its new chief financial officer, effective Dec. 19. Shares rise on this leadership transition.
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
CAMBRIDGE, Mass., Dec. 06, 2024 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc. ( Nasdaq: BEAM ) , a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer ( CFO ) , effective December 19, 2024.
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - Beam Therapeutics ( NASDAQ:BEAM ) , Assertio Holdings ( NASDAQ:ASRT )
CAMBRIDGE, Mass., Dec. 06, 2024 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc. BEAM, a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer ( CFO ) , effective December 19, 2024.
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down
IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024. Stock falls.
Ironwood Pharmaceuticals ( IRWD ) Misses Q3 Earnings Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of -77.78% and 2.94%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Op-ed: Here's why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors
Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don't think like your typical corporate board, writes Ken Squire of 13D Monitor.
Implied Volatility Surging for Ironwood ( IRWD ) Stock Options
Investors need to pay close attention to Ironwood (IRWD) stock based on the movements in the options market lately.
Ironwood Q2 Earnings & Revenues Fall Shy of Estimates - AstraZeneca ( NASDAQ:AZN ) , AbbVie ( NYSE:ABBV )
Ironwood Pharmaceuticals, Inc. IRWD reported break-even earnings for the second quarter of 2024 compared with the Zacks Consensus Estimate of earnings of 17 cents per share. The company had recorded adjusted earnings of 31 cents per share in the year-ago quarter.
Ironwood ( IRWD ) Q2 Earnings & Revenues Fall Shy of Estimates
Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates. The company lowers revenue guidance for 2024. Stock falls.
Ironwood Pharmaceuticals ( IRWD ) Reports Break-Even Earnings for Q2
Ironwood (IRWD) delivered earnings and revenue surprises of -100% and 9.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics ( HRTX ) Reports Q2 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -50% and 1.91%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ironwood Pharmaceuticals ( IRWD ) Q2 Earnings Expected to Decline
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
